Jane Street’s Metagenomi Therapeutics MGX Stock Holding History

Jane Street’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.7K	Sell	38,396 -113,044	-75%	-$151K	﹤0.01%	10972
2026 Q1	$203K	Sell	151,440 -282,419	-65%	-$439K	﹤0.01%	10120
2025 Q4	$703K	Buy	433,859 +335,604	+342%	+$726K	﹤0.01%	6952
2025 Q3	$233K	Sell	98,255 -60,676	-38%	-$123K	﹤0.01%	9386
2025 Q2	$235K	Buy	+158,931	New	+$249K	﹤0.01%	8277
2025 Q1	–	Sell	-29,758	Closed	-$107K	–	10839
2024 Q4	$107K	Buy	+29,758	New	+$71.8K	﹤0.01%	8738
2024 Q2	–	Sell	-12,330	Closed	-$130K	–	10336
2024 Q1	$130K	Buy	+12,330	New	+$142K	﹤0.01%	8425

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street's MGX Position: Q2 2026 in Review

Jane Street reduced its Metagenomi Therapeutics (MGX) stake by 75% in Q2 2026, selling an estimated $151K and leaving 38,396 shares worth $45.7K. The position accounts for ﹤0.01% of the portfolio, ranked #10972.

Jane Street first reported a position in MGX in Q1 2024 and has held it in 7 quarters since. The position peaked at $703K in Q4 2025. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Jane Street held 38,396 shares of Metagenomi Therapeutics worth $45.7K as of Q2 2026.
Jane Street sold 113,044 Metagenomi Therapeutics shares in Q2 2026, an estimated $151K.
Metagenomi Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10972 holding.
Jane Street first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 7 quarters since.
Jane Street's Metagenomi Therapeutics position peaked at $703K in Q4 2025.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.